Revagenix is advancing a proprietary pipeline of highly differentiated antibiotic programs in late preclinical stage, each with life-changing potential. Our product profiles are thoughtfully designed to address key unmet medical needs through a differentiated mechanism and/or modality, and to achieve meaningful use within the context of a complex clinical and reimbursement landscape.

Our lead program is a best-in-class agent developed using our proprietary chemistry platform. By applying our platform to a well-understood class of antibiotics, we have enabled the synthesis of previously impossible structures with differentiated antimicrobial activity. Currently in late preclinical stage, this broad spectrum agent is designed to address a range of infection types including cUTI, HABP/VABP, and neonatal sepsis/BSI.¹

Our second program is a first-in-class agent designed to reduce the burden of care in the treatment of chronic pulmonary infections.

We have an additional pipeline of multiple Gram-negative antibacterials, currently parked while we focus on our primary programs, and which we estimate ~12-18 months to candidate if activated.

1. This project has been funded in whole or in part with Federal funds from the National Institute of Allergy and Infectious Diseases, National Institutes of Health, Department of Health and Human Services, under Contract No. 75N93020C00018